Clinical Trial Search

Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…

Primary: Hypoglycemic Episodes — 1.9; 2.2 event rate per person-week — p=<0.0001

Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06

Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86

Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes

Primary: Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week…

Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05

Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012

Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002

Primary: Percentage of Slow Wave Entrainment — 72; 70; 84; 78 percentage of slow waves entrainment

Primary: Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 4; 3; 4 Participants

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL

Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants

Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants

Primary: Change From Baseline of Nausea Severity Score — -3.55; -3.65; -3.43; -2.83 units on a scale — p=0.1350

Primary: Change From Baseline to Week 12 in Weekly Vomiting Episodes — 5.7; 7.7; 6.9; 4.8 vomiting episodes per week — p=0.36

Primary: The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)…

Primary: Response in Glucose AUC at Baseline vs. Following Gastric Bypass Surgery — 61647.0; 59476.1 mg/dL*min

Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml

Primary: Uptake of 11C-ER 176 in the Stomach Muscle — 5.5; 8.4; 4.6; 7.8 SUVmax

Primary: Change From Baseline in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) Composite Score at Week…

Primary: Change From Baseline in Average Nausea Severity — -1.25; -0.73 score on a scale (change from baseline) — p=.0099

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score

Primary: Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14 — 293.5; 345.6; 1.3; 2.0 mL — p=0.9030

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69

Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01

Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01